GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

IMDX · Jun 30, 2024

Insight Molecular Diagnostics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-24-030793General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

183.65% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-5748.08% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-77.54% · CORE · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

48.08% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-4453.85% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

2358.65% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

371.15% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/5 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20245/8 normalizedLevel 3Mar 31, 20255/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
13.64%
Current
183.65%
Delta
170.02%
Cash Generation Decreased
Previous
-2176.14%
Current
-5748.08%
Delta
-3571.94%
Growth Decreased
Previous
-40.74%
Current
-77.54%
Delta
-36.80%
Margin Increased
Previous
-55.68%
Current
48.08%
Delta
103.76%
Profitability Increased
Previous
-5265.34%
Current
-4453.85%
Delta
811.49%
R And D Intensity Increased
Previous
1232.39%
Current
2358.65%
Delta
1126.27%
Sbc Intensity Increased
Previous
237.50%
Current
371.15%
Delta
133.65%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · IMDX Fundamental State →Transitioned To · IMDX Fundamental State →Transitioned To · IMDX CAPEX_INTENSITY_INCREASED →Transitioned To · IMDX CASH_GENERATION_DECREASED →Transitioned To · IMDX GROWTH_DECREASED →Transitioned To · IMDX MARGIN_INCREASED →Transitioned To · IMDX PROFITABILITY_INCREASED →Transitioned To · IMDX R_AND_D_INTENSITY_INCREASED →Transitioned To · IMDX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.